

Studies currently open to recruitment

Medicine

Specialty Area	Principal Investigator	Lead Research Contact	Name of study	Brief description of the study
Gastroenterology	Dr Anurag Agrawal	Gemma Kirkman	BI 655130	A Phase II/III Randomised, Double-blind, Placebo-controlled, multicentre Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics therapy
	Dr Anurag Agrawal	Gemma Kirkman	BI 655130 extension	BI 655130 long-term treatment in patients with moderate-to severe ulcerative colitis
	Dr Anurag Agrawal	Lisa Warren	RELIEVE	Randomised, multi-centre study to assess effectiveness, tolerability and safety of Enterosgel in the treatment of Irritable Bowel Syndrome with diarrhoea (IBS-D) in adults
	Dr Joanna Sayer	Rebecca Pugh	PBC	The PBC Genetics Study is a national effort to establish a PBC DNA collection consisting of DNA samples from approximately 5000 patients with PBC. The DNA collection has already been used for a genome-wide association study (GWAS) of PBC. The next major analysis will be a genome wide association study of response to Ursodeoxycholic acid (UDCA)
Cardiology	Dr Alastair Cooke	Deborah Walstow	Ironman	This study is looking to establish whether patients with chronic heart failure and iron deficiency and treated with intravenous iron is effective in reducing

				death due to cardiovascular problems, and hospitalisation due to heart failure
Rheumatology	Dr Chee-Seng Yee	Rebecca Pugh	BEAT Lupus	This study aims to find out whether a drug called Belimumab when used after B cell depletion therapy is safe and effective in reducing systemic lupus erythematosus (lupus) disease activity
	Dr Robert Stevens	Gillian Herdman	BSRBR	The BSRBR-RA study tracks the progress of people with rheumatoid arthritis (RA) who have been prescribed biologic (including biosimilar) and other targeted therapies in the UK, to monitor the long-term safety of these drugs
	Dr Chee-Seng Yee	Gillian Herdman	BILAG BR	The BILAG Biologics Prospective Cohort is a prospective observational cohort study of patients with SLE who are starting treatment with a biologic drug or a conventional, non-biologic therapy
	Dr Chee-Seng Yee	Gillian Herdman	GCA	This is designed as an immunogenetic study of giant cell arteritis and polymyalgia rheumatica. The ultimate aim is to conduct a genome-wide association study of these diseases
	Dr Chee-Seng Yee	-	UKIVAS	Development of a Pan UK Vasculitis Cohort to Analyse Variations in Disease Susceptibility and Outcomes
	Dr Chee-Seng Yee	Gillian Herdman	MYOPROSP	A prospective cohort study to identify a stratified approach in the diagnosis, treatment and delivery of care in adult idiopathic

	Dr Chee-Seng Yee	Gillian Herdman	UKMYONET	inflammatory myopathy Identification of disease susceptibility genes associated with development and clinical characteristics of primary inflammatory muscle diseases, PM, DM and IBM
	Dr Chee-Seng Yee	Veronica Maxwell	PRINT	The purpose of this study is to try and identify inflammatory factors that increase disease activity and adverse pregnancy outcomes in pregnancy to allow us to develop new predictive tests and to study safety of anti-rheumatic drugs in pregnancy and breastfeeding
	Dr Chee-Seng Yee	Rosanna Fong	AZ SPOCS	Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study
	Dr Chee-Seng Yee	Rebecca Pugh	COMPACT	A multicenter, prospective, observational cohort study to evaluate the real-world safety and effectiveness of Erelzi™, an etanercept biosimilar
	Dr Chee-Seng Yee		RA BE REAL	The purpose of this study is to assess the effectiveness of Olumiant (baricitinib) and certain other treatments for rheumatoid arthritis and the effect, if any, on physical functioning, quality of life, and pain associated with rheumatoid arthritis. The healthcare resources required for treating and managing rheumatoid arthritis and the associated costs will also be explored.
Dermatology	Dr Trupti Desai	Gillian Herdman	BADBIR	British Association of Dermatologists Biologic Interventions Register
	Dr Trupti Desai	Gillian Herdman	BSTOP	Our overall research aim therefore seeks to discover which gene(s) are

important in determining good (or poor) responses to the drugs that are used to treat psoriasis, and to identify markers (genetic or otherwise) of treatment outcomes.

Haematology	Dr Joe Joseph	Haematology Specialist Nurses	LI-1	LI (less intensive)-1 will evaluate several relevant therapeutic questions in Acute Myeloid Leukemia (AML) as defined by the WHO and High-Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years for whom conventional chemotherapy is not considered suitable. The trial is part of a continuous program of development aimed at improving the outcomes of treatment in this patient population.
	Dr Joe Joseph	Haematology Specialist Nurses	FLAIR	This is a phase III, multicentre, randomised, controlled, open, parallel group trial in patients with previously untreated CLL.
	Dr Joe Joseph	Haematology Specialist Nurses	AML19	Looking at adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome
	Dr Joe Joseph	Haematology Specialist Nurses	Registry of patients treated with Pomalidomide	A registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Renal	Dr Ian Stott	Sharon Allen	RADAR	Registry to the National Studies of Rare Kidney Diseases
	Dr Mohsen El	Gemma	ASCEND ID	This Phase 3 study will

Kossi	Kirkman		evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin in the treatment of anemia associated with chronic kidney disease in subjects who are planning to start or who have recently started dialysis.
Dr Mohsen El Kossi	Gemma Kirkman	ASCEND ND	A phase 3 randomized, study to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
Dr Mohsen El Kossi	Gemma Kirkman	Pro2tect-Correction	Phase 3 study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease.
Dr Mohsen El Kossi	Gemma Kirkman	Pro2tect-Conversion	Phase 3 study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease.
Dr Mohsen El Kossi	Gemma Kirkman	INNO2VATE	Phase 3 study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease.
Dr Mohsen El Kossi	Gemma Kirkman	TRCA303 VALOR-CKD	A Phase 3b study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis,
Mr Muhammad Kanaa	Rosanna Fong	SIMPLIFIED	This study will test what impact supplementation with cholecalciferol has on dialysis patients.
Mr	Specialist	UK	Calciphylaxis is a rare

	Muhammad Kanaa	Nurses	Calciphylaxis	condition which results in small arteries becoming calcified. The study will collect patient information on medications, clinical parameters, local laboratory tests, measuring specific proteins and molecules in blood and tissue as well as studying DNA profiles.
Diabetes	Dr Pankaj Chaturvedi	Veronica Maxwell	PATHFINDER	Lysosomal acid lipase (LAL) deficiency is a rare enzyme deficiency that is associated with premature vascular disease. Every day thousands of pathology tests are carried out in laboratories across the country. This still will identify if that data could be linked to identify features that may be suggestive of a rare disease. The result may well lead to screening programs to find people who could benefit from early treatment.
Stroke	Dr Dinesh Chadha	Deborah Walstow	LACI-2	This is a stroke study where patients have a 'lacunar' or 'small vessel' stroke, which is different to other common types of stroke and for which there is no proven treatment. Small vessel stroke is caused by damage to the lining of the tiny blood vessels in the brain that stops the vessels functioning normally and damages the brain. This study will look to see if 2 particular drugs which are commonly used in other vessel diseases may help improve small vessel function and prevent worsening of brain damage.
	Dr Dinesh	Deborah	DNA Lacunar	This stroke study is looking

Chadha

Walstow

at patients who have had a Lacunar Stroke. DNA will be collected and screened for notch 3 mutations. A second sample will be sent to ECCAC for storage for future cell line production to allow unlimited supplies of DNA.

Dr Peter Anderton

Deborah Walstow

PLORAS

The aim of the study is to provide a clinical protocol that will Predict Language Outcome and Recovery After Stroke (PLORAS). The system being developed takes a structural brain image of a new patient with language difficulties (aphasia) and produces probabilistic estimates of long term outcome, based on whether, when, and in what respects, other patients with “matching” lesions recovered their speech and language abilities.

Brains for Dementia
TONIC

Open
Open

Harkness, Dr Kirsty
Paling, Dr David

Clinical Specialities
Surgery & Cancer

Surgery and Cancer

Specialty Area	Principal Investigator	Lead Research Contact	Name of study	Brief description of the study
Urology	Dr Carmel Pezaro	Nicola Wilkinson	STAMPEDE	
	Mr Ramanan Rajasundaram	Nicola Wilkinson	UK Genetic Prostate Cancer	
	Mr Ramanan Rajasundaram	Nicola Wilkinson	Life and Bladder Cancer	
	Mr Ramanan Rajasundaram	Nicola Wilkinson	BRAVO	
	Prof Lynda Wyld	Jennifer Taylor	MIAMI	
	Prof Lynda Wyld	Jennifer Taylor	Fingertip smear	
	Ms Clare Rogers	Jennifer Taylor	POSNOG	

	Dr Simon Pledge	Lisa Warren / Sharon Allen	SEARCH	
	Dr Bernadette Foran	Nicola Wilkinson	Head & Neck 5000 follow up	
Orthopaedics	Mr Sanjeev Madan	Gemma Kirkman	ACTIVE	
	Mr Sanjeev Madan	Gemma Kirkman	Improving bone marrow stem cells performance	
	Mr Sanjeev Madan	Gemma Kirkman	BOSS Study	
	Mr Sanjeev Madan	Gemma Kirkman	ATM	
Surgery	Mr Tim Wilson	Veronica Maxwell	Yorkshire Cancer Research Bowel Cancer Improvement Programme	
	Mr Tim Wilson	Veronica Maxwell	FAST TRACK	
	Mr Tim Wilson	Veronica Maxwell	CIPHER	
	Mr Srinivasan Balchandra	-	DOME	
	Mr Duncan Drury	Specialist Nurses	Altitude	
	MR Paul Haslam	Gemma Kirkman	ASCRIBED	
Vascular	Mr Willy Pillay	Specialist Nurses	BASIL 2	

Clinical Specialities

Specialty Area	Principal Investigator	Lead Research Contact	Name of study	Brief description of the study
Anaesthetics	Mr Paul Bedford	Nicola Wilkinson	PQIP	
Physiotherapy	Julie Bury	Physios	GRASP	
Pathology	Dr Ken Agwuh	-	COMBACTE-CDI	

Children and Families

Specialty Area	Principal Investigator	Lead Research Contact	Name of study	Brief description of the study
----------------	------------------------	-----------------------	---------------	--------------------------------

Paediatrics	Dr Anuja Natarajan	Sharon Allen / Lisa Warren	TrialNet
	Dr Anuja Natarajan	Sharon Allen / Lisa Warren	GOOS
	Dr Anuja Natarajan	Sharon Allen / Lisa Warren	Active CHILD
	Dr Michael Hayes	Sharon Allen / Lisa Warren	Petechiae In Children (PIC) Study
	Dr Razia Petkar	Sharon Allen / Lisa Warren	UK Childhood ITP Registry
	Dr Sabitha Lakshminarayanan	Sharon Allen / Lisa Warren	Parental mindfulness
GU Meds	Dr Claire Ryan	Specialist Nurses	PrEP
	Dr Claire Ryan	Specialist Nurses	CHIPS+
Gynae	Ms Manju Singh	Gemma Kirkman	PRE-EMPT
Maternity	Joanne Hadley	Specialist Nurses	PreCePT
	Lynne Crewe	-	Cleft Collective
	Maria Crilley	-	Normal Birth Survey
	Ms Natalie Khoaz	-	Breech Birth